+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab



Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab



Clinical Cancer Research 10(11): 3577-3585



Vascular endothelial growth factor (VEGF) promotes acute myelogenous leukemia (AML) cell growth and survival and may contribute to drug resistance. bevacizumab, an anti-VEGF monoclonal antibody, exhibits clinical activity against diverse malignancies when administered with cytotoxic chemotherapy. We conducted a Phase II clinical trial of bevacizumab administered after chemotherapy to adults with refractory or relapsed AML, using a timed sequential therapy (TST) approach. bevacizumab 10 mg/kg was administered on day 8 after 1-beta-d-arabinofuranosylcytosine 2 g/m(2)/72 h beginning day 1 and mitoxantrone 40 mg/m(2) beginning day 4. In vivo laboratory correlates included AML cell VEGF receptor-1 (FLT-1) expression, marrow microvessel density, and free serum VEGF before and during TST with bevacizumab. Forty-eight adults received induction therapy. Myelosuppression occurred in all of the patients similar to other TST regimens. Toxicities were decreased ejection fraction (6%), cerebrovascular bleed (4%), and mortality of 15%. Overall response was 23 of 48 (48%), with complete response (CR) in 16 (33%). Eighteen (14 CR and 4 partial response) underwent one consolidation cycle and 5 (3 CR and 2 partial response) underwent allogeneic transplant. Median overall and disease-free survivals for CR patients were 16.2 months (64%, 1 year) and 7 months (35%, 1 year). Marrow blasts demonstrated FLT-1 staining before bevacizumab and marked decrease in microvessel density after bevacizumab. VEGF was detected in pretreatment serum in 67% of patients tested, increased by day 8 in 52%, and decreased in 93% (67% undetectable) 2 h after bevacizumab. In this single arm study, cytotoxic chemotherapy followed by bevacizumab yields a favorable CR rate and duration in adults with AML that is resistant to traditional treatment approaches. The clearance of marrow blasts in some patients after bevacizumab suggests that VEGF neutralization might result directly in leukemic cell death. The potential biological and clinical activity of bevacizumab in AML warrants additional clinical and laboratory study.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 050501217

Download citation: RISBibTeXText

PMID: 15173063

DOI: 10.1158/1078-0432.ccr-03-0627


Related references

Timed Sequential Therapy of Relapsed and Refractory Adult Acute Myelogenous Leukemia with the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab. Blood 100(11): Abstract No 744, 2002

Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Clinical Cancer Research 11(23): 8403-8412, 2005

Sequential mitoxantrone, Ara-C and VP-16, followed by immuno-maintenance-therapy with interleukin-2 in the treatment of refractory and relapsed acute myelogenous leukemia. Annals of Hematology 68(2): A32, 1994

Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. Current Cancer Drug Targets 5(4): 229-248, 2005

Antiangiogenic Therapy in Acute Myelogenous Leukemia: Targeting of Vascular Endothelial Growth Factor and Interleukin 8 as Possible Antileukemic Strategies. Current Cancer Drug Targets 5(4): 229-248, 2005

Mitoxantrone, etoposide and cyclosporine A therapy for relapsed and refractory acute myelogenous leukemia , a Pediatric Oncology Group phase II trial. Annals of Hematology 68(2): A32, 1994

A Pediatric Oncology Group Phase II trial of Mitoxantrone, Etoposide and Cyclosporine A therapy for relapsed and refractory acute myelogenous leukemia. Proceedings of the American Association for Cancer Research Annual Meeting 35: 332, 1994

Mitoxantrone in relapsed or refractory acute myelogenous leukemia. Leukemia 1(3): 278, 1987

Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia. Annals of Hematology 77(3): 115-122, 1998

A pilot study of combination chemotherapy with N-4-behenoyl-1-beta-D-arabinofuranosylcytosine aclacinomycin A and prednisolone for refractory adult acute myelogenous leukemia. Blood 86(10 Suppl. 1): 756A, 1995

Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia. Leukemia 7(3): 372-377, 1993

Phase i ii study of quinine associated with mitoxantrone and aracytine in refractory and relapsed acute leukemias. Proceedings of the American Association for Cancer Research Annual Meeting 33: 236, 1992

The Efficacy of Fludarabine, High Dose Cytosine Arabinoside with Granulocyte Colony Stimulating Factor (FLAG) Protocol as Salvage Therapy for Refractory/Relapsed Acute Leukemias in Adult Iraqi Patients. Indian Journal of Hematology and Blood Transfusion 30(4): 231-235, 2014

Mitoxantrone and etoposide an effective regimen for refractory or relapsed acute myelogenous leukemia. European Journal of Haematology 43(5): 411-416, 1989

Sequential therapy with idarubicin cytarabin and mitoxantrone etoposide for adult acute myelogenous leukemia a pilot study. Journal of Cancer Research & Clinical Oncology 116(Suppl. Part 1): 595, 1990